$0.32−0.03 (−7.63%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Redhill Biopharma (RDHL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 100% below its peak, net margin −150.0%.
The four lines that matter · FY21–FY25
Revenue ($K)—
286.0
FY21→FY25CAGR −76.0%/yr
Net income ($K)▲94.8%
−429.0
FY21→FY25CAGR —
Free cash flow ($K)—
—
no FY25 valueCAGR —
Diluted EPS—
0.00
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%
50.9bn → 50.9bn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-150¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -150.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 286.0 | 0.0 | 0.0 | 61,800.0 | 85,757.0 | — | −76.0% |
Cost of revenue | 0.0 | 0.0 | 0.0 | 33,337.0 | 49,406.0 | — | — |
Gross profit | — | — | — | 28,463.0 | 36,351.0 | — | — |
Research & development | 2,023.0 | 1,588.0 | 3,529.0 | 7,279.0 | 29,498.0 | ▲27.4% | −48.8% |
Selling, general & admin | 6,172.0 | 4,887.0 | 6,019.0 | 28,586.0 | 32,365.0 | ▲26.3% | −33.9% |
Total operating expenses | 8,195.0 | 6,475.0 | 9,548.0 | 71,307.0 | 117,486.0 | ▲26.6% | −48.6% |
Operating incomefeeds ROC rank | −7,942.0 | −6,475.0 | −9,548.0 | −42,844.0 | −81,135.0 | ▼22.7% | — |
Other income, net | −171.0 | 6,835.0 | −8,950.0 | −28,825.0 | −16,609.0 | — | — |
Pretax income | −8,113.0 | 360.0 | −18,498.0 | −71,669.0 | −97,744.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −429.0 | −8,268.0 | 23,916.0 | −71,669.0 | −97,744.0 | ▲94.8% | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | 0.00 | 0.00 | — | −0.12 | −0.21 | — | — |
Diluted shares (bn) | 50.92 | 12.90 | — | 1.18 | 0.53 | ▲294.8% | — |
| Margins | |||||||
Gross margin80th pct in Healthcare | — | — | — | 46.1% | 42.4% | — | — |
Operating margin | −2776.9% | — | — | −69.3% | −94.6% | — | — |
Net margin21st pct in Healthcare | −150.0% | — | — | −116.0% | −114.0% | — | — |
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-04-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Redhill Biopharma's net income?
Redhill Biopharma reported net income of −$429.0K in fiscal 2025, a net margin of −150.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

